Position in ABVX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$478,805
+$33,784 QoQ
Shares Held
4,300
+30.3% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARVEY CAPITAL MANAGEMENT INC holds $41,212,465 across 6 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
146,113 | $11,436,264 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
138,835 | $10,340,430 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
26,913 | $6,485,225 | |
| 4 | CYTK |
Cytokinetics Inc
|
68,275 | $5,816,347 | |
| 5 | ARGX |
Argenx SE
|
4,346 | $4,032,088 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,975 | $3,102,111 |
All Filings in ABVX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $478,805 | 4,300 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $445,021 | 3,300 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||